Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis

Authors Cope S, Capkun-Niggli G, Gale R, Jardim J, Jansen J

Published 8 June 2011 Volume 2011:6 Pages 329—344


Review by Single anonymous peer review

Peer reviewer comments 2

Shannon Cope1, Gorana Capkun-Niggli2, Rupert Gale3, José R Jardim4, Jeroen P Jansen1
Mapi Values, Boston, MA, USA; 2Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland; 3Novartis Horsham Research Centre, Horsham, UK; 4Respiratory Division, Federal University of São Paulo, Brazil

Objective: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs).
Methods: Fifteen placebo-controlled RCTs were included that evaluated: indacaterol 150 µg (n = 5 studies), indacaterol 300 µg (n = 4), FOR/BUD 9/160 µg (n = 2), FOR/BUD 9/320 µg (n = 3), SAL/FP 50/500 µg (n = 5), and SAL/FP 50/250 µg (n = 1). Outcomes of interest were trough forced expiratory volume in 1 second (FEV1), total scores for St. George's Respiratory Questionnaire (SGRQ), and transition dyspnea index (TDI). All trials were analyzed simultaneously using a Bayesian network meta-analysis and relative treatment effects between all regimens were obtained. Treatment-by-covariate interactions were included where possible to improve the similarity of the trials.
Results: Indacaterol 150 µg resulted in a higher change from baseline (CFB) in FEV1 at 12 weeks compared to FOR/BUD 9/160 µg (difference in CFB 0.11 L [95% credible intervals: 0.08, 0.13]) and FOR/BUD 9/320 µg (0.09 L [0.06, 0.11]) and was comparable to SAL/FP 50/250 µg (0.02 L [0.04, 0.08]) and SAL/FP 50/500 µg (0.03 L [0.00, 0.06]). Similar results were observed for indacaterol 300 µg at 12 weeks and indacaterol 150/300 µg at 6 months. Indacaterol 150 µg demonstrated comparable improvement in SGRQ total score at 6 months versus FOR/BUD (both doses), and SAL/FP 50/500 µg (2.16 point improvement [4.96, 0.95]). Indacaterol 150 and 300 µg demonstrated comparable TDI scores versus SAL/FP 50/250 µg (0.21 points (0.57, 0.99); 0.39 [0.39, 1.17], respectively) and SAL/FP 50/500 µg at 6 months.
Conclusion: Indacaterol monotherapy is expected to be at least as good as FOR/BUD (9/320 and 9/160 µg) and comparable to SAL/FP (50/250 and 50/500 µg) in terms of lung function. Indacaterol is also expected to be comparable to FOR/BUD (9/320 and 9/160 µg) and SAL/FP 50/500 µg in terms of health status and to SAL/FP (50/250 and 50/500 µg) in terms of breathlessness.

Keywords: COPD, network meta-analysis, indacaterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.